Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications

摘要: A novel coronavirus-2 (SARS-CoV-2) was first identified in Wuhan, China, and quickly spread globally. Several treatments have been proposed, many of which proven ineffective. Consequently, there is a need to review the published evidence drug clinical trials guide future prescribing. systematic retrospective observational studies carried out. The search made using PubMed, Embase, MEDLINE, China National Knowledge Infrastructure (CNKI) databases. Articles between January 2020 October written English language were retrieved included study. Researches that used traditional medicine, in-vitro in-vivo animal studies, as well reviews excluded. Seventy-three relevant articles fulfilled inclusion criteria finally selected reviewed. Hydroxychloroquine, chloroquine, azithromycin produced no efficacy randomized controlled (RCT). However, reported remdesivir lopinavir/ritonavir reducing viral load, although concerns with and, more recently, remdesivir. Recently, tocilizumab, dexamethasone, methylprednisolone significantly relieved lung inflammation decreased mortality patients severe COVID-19. In addition, convalescent plasma effective boosting strong immunity among mild There currently single worldwide approved therapeutic option for COVID-19 despite initial hype medicines, including hydroxychloroquine. Nonetheless, dexamethasone has shown promise symptomatic treatment immunity. New are being researched, findings will be accordingly provide evidence-based guidance prescribers policymakers.